nach oben

Der Nervenarzt

Erschienen in:

01.12.2015 | CME Zertifizierte Fortbildung

Periphere, zentrale und funktionelle Schwindelsyndrome

verfasst von: Prof. Dr. Dr. h.c. M. Strupp, FANA, FEAN, M. Dieterich, A. Zwergal, T. Brandt

Erschienen in: Der Nervenarzt | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

In Abhängigkeit vom zeitlichen Verlauf lassen sich drei Formen von Schwindelsyndromen unterscheiden: 1) Schwindelattacken (z. B. benigner peripherer paroxysmaler Lageschwindel [BPPV], Morbus Menière, vestibuläre Migräne), 2) akut einsetzender über Tage anhaltender Schwindel (z. B. akute einseitige Vestibulopathie, Hirnstamm- oder Kleinhirninfarkt), 3) über Monate bis Jahre dauernde Symptome (z. B. bilaterale Vestibulopathie, funktioneller Schwindel). Die spezifische Therapie der verschiedenen Syndrome beruht im Wesentlichen auf drei Prinzipen: 1) physikalische Behandlung mit Befreiungsmanövern bei BPPV und Balancetraining bei vestibulärem Defizit; 2) Pharmakotherapie z. B. bei akuter einseitiger Vestibulopathie (Kortikosteroide) oder Morbus Menière (transtympanale Gentamycin- oder Steroidapplikation, Hochdosistherapie mit Betahistin); placebokontrollierte Pharmakotherapiestudien werden derzeit für akute einseitige Vestibulopathie, Vestibularisparoxysmie, Prophylaxe des BPPV, vestibuläre Migräne, episodische Ataxie Typ 2 und zerebelläre Ataxien durchgeführt; 3) Psychotherapie bei funktionellem Schwindel.

Bisdorff A, Brevern M von, Lempert T et al (2009) Classification of vestibular symptoms: towards an international classification of vestibular disorders. J Vestib Res 19(1–2):1–13

Strupp M, Dieterich M, Zwergal A, Brandt T (2015) Diagnosestellung und Therapieoptionen von Schwindelsyndromen. Nervenarzt 86:1277–1290CrossRefPubMed

Diener HC, Weimar C (2012) Leitlinien für Diagnostik und Therapie in der Neurologie, 5. Aufl. Thieme, Stuttgart

Brandt T, Dieterich M, Strupp M (2012) Vertigo – Leitsymptom Schwindel, 2. Aufl. Springer Medizin, Heidelberg

Brandt T, Strupp M, Dieterich M (2014) Five keys for diagnosing most vertigo, dizziness, and imbalance syndromes: an expert opinion. J Neurol 261(1):229–231CrossRefPubMed

Jeong SH, Kim JS, Shin JW et al (2013) Decreased serum vitamin D in idiopathic benign paroxysmal positional vertigo. J Neurol 260(3):832–838CrossRefPubMed

Bremova T, Bayer O, Agrawal Y et al (2013) Ocular VEMPs indicate repositioning of otoconia to the utricle after successful liberatory maneuvers in benign paroxysmal positioning vertigo. Acta Otolaryngol 133(12):1297–1303PubMedCentralCrossRefPubMed

Kim JS, Oh SY, Lee SH et al (2012) Randomized clinical trial for apogeotropic horizontal canal benign paroxysmal positional vertigo. Neurology 78(3):159–166CrossRefPubMed

Imai T, Ito M, Takeda N et al (2005) Natural course of the remission of vertigo in patients with benign paroxysmal positional vertigo. Neurology 64(5):920–921CrossRefPubMed

10.

Shim DB, Ko KM, Lee JH et al (2015) Natural history of horizontal canal benign paroxysmal positional vertigo is truly short. J Neurol 262(1):74–80CrossRefPubMed

11.

Brandt T, Huppert D, Hecht J et al (2006) Benign paroxysmal positioning vertigo: a long-term follow-up (6–17 years) of 125 patients. Acta Otolaryngol 126(2):160–163CrossRefPubMed

12.

Brandt T, Dieterich M (1994) Vestibular paroxysmia: vascular compression of the eighth nerve? Lancet 343(8900):798–799CrossRefPubMed

13.

Hufner K, Barresi D, Glaser M et al (2008) Vestibular paroxysmia: diagnostic features and medical treatment. Neurology 71(13):1006–1014CrossRefPubMed

14.

Strupp M, Stuckrad-Barre S von, Brandt T, Tonn JC (2013) Teaching neuroimages: compression of the eighth cranial nerve causes vestibular paroxysmia. Neurology 80(7):e77CrossRefPubMed

15.

Best C, Gawehn J, Kramer HH et al (2013) MRI and neurophysiology in vestibular paroxysmia: contradiction and correlation. J Neurol Neurosurg Psychiatry 84(12):1349–1356CrossRefPubMed

16.

Lopez-Escamez JA, Carey J, Chung WH et al (2015) Diagnostic criteria for Meniere’s disease. J Vestib Res 25(1):1–7PubMed

17.

Gurkov R, Flatz W, Louza J et al (2011) In vivo visualization of endolyphatic hydrops in patients with Meniere’s disease: correlation with audiovestibular function. Eur Arch Otorhinolaryngol 268(12):1743–1748CrossRefPubMed

18.

Huppert D, Strupp M, Brandt T (2010) Long-term course of Meniere’s disease revisited. Acta Otolaryngol 130(6):644–651CrossRefPubMed

19.

Strupp M, Thurtell MJ, Shaikh AG et al (2011) Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus. J Neurol 258(7):1207–1222PubMedCentralCrossRefPubMed

20.

Stokroos R, Kingma H (2004) Selective vestibular ablation by intratympanic gentamicin in patients with unilateral active Meniere’s disease: a prospective, double-blind, placebo-controlled, randomized clinical trial. Acta Otolaryngol 124(2):172–175CrossRefPubMed

21.

Postema RJ, Kingma CM, Wit HP et al (2008) Intratympanic gentamicin therapy for control of vertigo in unilateral Menire’s disease: a prospective, double-blind, randomized, placebo-controlled trial. Acta Otolaryngol 128(8):876–880CrossRefPubMed

22.

Pullens B, Benthem PP van (2011) Intratympanic gentamicin for Meniere’s disease or syndrome. Cochrane Database Syst Rev 3:CD008234PubMed

23.

Garduno-Anaya MA, Couthino De TH, Hinojosa-Gonzalez R et al (2005) Dexamethasone inner ear perfusion by intratympanic injection in unilateral Meniere’s disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg 133(2):285–294CrossRefPubMed

24.

Casani AP, Piaggi P, Cerchiai N et al (2012) Intratympanic treatment of intractable unilateral Meniere disease: gentamicin or dexamethasone? A randomized controlled trial. Otolaryngol Head Neck Surg 146(3):430–437CrossRefPubMed

25.

Bertlich M, Ihler F, Freytag S et al (2015) Histaminergic H-Heteroreceptors as a Potential Mediator of Betahistine-Induced Increase in Cochlear Blood Flow. Audiol Neurootol 20(5):283–293CrossRefPubMed

26.

Nauta JJ (2014) Meta-analysis of clinical studies with betahistine in Meniere’s disease and vestibular vertigo. Eur Arch Otorhinolaryngol 271(5):887–897CrossRefPubMed

27.

Strupp M, Zwergal A, Feil K et al (2015) Pharmacotherapy of vestibular and cerebellar disorders and downbeat nystagmus: translational and back-translational research. Ann N Y Acad Sci 1343(1):27–36CrossRefPubMed

28.

Ihler F, Bertlich M, Sharaf K et al (2012) Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in Guinea pigs in vivo. PLoS One 7(6):e39086PubMedCentralCrossRefPubMed

29.

Bertlich M, Ihler F, Sharaf K et al (2014) Betahistine metabolites, Aminoethylpyridine, and Hydroxyethylpyridine increase cochlear blood flow in guinea pigs in vivo. Int J Audiol 53(10):753–759CrossRefPubMed

30.

Lempert T, Olesen J, Furman J et al (2012) Vestibular migraine: diagnostic criteria. J Vestib Res 22(4):167–172PubMed

31.

Maldonado FM, Birdi JS, Irving GJ et al (2015) Pharmacological treatment for the prevention of vestibular migraine. Cochrane Database Syst Rev (Im Druck)

32.

Jen JC, Graves TD, Hess EJ et al (2007) Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain 130(Pt 10):2484–2493CrossRefPubMed

33.

Strupp M, Zwergal A, Brandt T (2007) Episodic ataxia type 2. Neurotherapeutics 4(2):267–273CrossRefPubMed

34.

Strupp M, Kalla R, Dichgans M et al (2004) Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 62(9):1623–1625CrossRefPubMed

35.

Strupp M, Kalla R, Claassen J et al (2011) A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 77(3):269–275PubMedCentralCrossRefPubMed

36.

Claassen J, Teufel J, Kalla R et al (2013) Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study. J Neurol 260(2):668–669CrossRefPubMed

37.

Cnyrim CD, Newman-Toker D, Karch C et al (2008) Bedside differentiation of vestibular neuritis from central „vestibular pseudoneuritis“. J Neurol Neurosurg Psychiatry 79(4):458–460CrossRefPubMed

38.

Kattah JC, Talkad AV, Wang DZ et al (2009) HINTS to diagnose stroke in the acute vestibular syndrome: three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging. Stroke 40(11):3504–3510PubMedCentralCrossRefPubMed

39.

Strupp M, Magnusson M (2015) Acute Unilateral Vestibulopathy. Neurol Clin 33(3):669–685CrossRefPubMed

40.

Beck R, Gunther L, Xiong G et al (2014) The mixed blessing of treating symptoms in acute vestibular failure – evidence from a 4-aminopyridine experiment. Exp Neurol 261:638–645CrossRefPubMed

41.

Strupp M, Zingler VC, Arbusow V et al (2004) Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med 351(4):354–361CrossRefPubMed

42.

Karlberg ML, Magnusson M (2011) Treatment of acute vestibular neuronitis with glucocorticoids. Otol Neurotol 32(7):1140–1143CrossRefPubMed

43.

Fishman JM, Burgess C, Waddell A (2011) Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane Database Syst Rev 5:CD008607PubMed

44.

Strupp M, Arbusow V, Maag KP et al (1998) Vestibular exercises improve central vestibulospinal compensation after vestibular neuritis. Neurology 51(3):838–844CrossRefPubMed

45.

Hillier SL, McDonnell M (2011) Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database Syst Rev 2:CD005397PubMed

46.

Brandt T, Huppert T, Hufner K et al (2010) Long-term course and relapses of vestibular and balance disorders. Restor Neurol Neurosci 28(1):69–82PubMed

47.

Huppert D, Strupp M, Theil D et al (2006) Low recurrence rate of vestibular neuritis: a long-term follow-up. Neurology 67(10):1870–1871CrossRefPubMed

48.

Kim YH, Kim KS, Kim KJ et al (2011) Recurrence of vertigo in patients with vestibular neuritis. Acta Otolaryngol 131(11):1172–1177CrossRefPubMed

49.

Arbusow V, Theil D, Strupp M et al (2000) HSV-1 not only in human vestibular ganglia but also in the vestibular labyrinth. Audiol Neurootol 6(5):259–262CrossRef

50.

Brandt T, Schautzer F, Hamilton D et al (2005) Vestibular loss causes hippocampal atrophy and impaired spatial memory in humans. Brain 128:2732–2741CrossRefPubMed

51.

Zingler VC, Cnyrim C, Jahn K et al (2007) Causative factors and epidemiology of bilateral vestibulopathy in 255 patients. Ann Neurol 61(6):524–532CrossRefPubMed

52.

Kirchner H, Kremmyda O, Hufner K et al (2011) Clinical, electrophysiological, and MRI findings in patients with cerebellar ataxia and a bilaterally pathological head-impulse test. Ann N Y Acad Sci 1233(1):127–138CrossRefPubMed

53.

Wagner JN, Glaser M, Brandt T, Strupp M (2008) Downbeat nystagmus: aetiology and comorbidity in 117 patients. J Neurol Neurosurg Psychiatry 79(6):672–677CrossRefPubMed

54.

Zingler VC, Weintz E, Jahn K et al (2007) Follow-up of vestibular function in bilateral vestibulopathy. J Neurol Neurosurg Psychiatry 79:284–288CrossRefPubMed

55.

Brandt T, Dieterich M (1986) Phobischer Attacken-Schwankschwindel, ein neues Syndrom. Münch Med Wochenschr 128:247–250

56.

Brandt T (1996) Phobic postural vertigo. Neurology 46(6):1515–1519CrossRefPubMed

57.

Brandt T, Huppert D, Strupp M, Dieterich M (2015) Functional dizziness: diagnostic keys and differential diagnosis. J Neurol 262(8):1977–1980CrossRefPubMed

58.

Feuerecker R, Habs M, Dieterich M, Strupp M (2015) Chronic subjective dizziness: fewer symptoms in the early morning – a comparison with bilateral vestibulopathy and downbeat nystagmus syndrome. J Vestib Res (Im Druck)

59.

Huppert D, Strupp M, Rettinger N et al (2005) Phobic postural vertigo – a long-term follow-up (5–15 years) of 106 patients. J Neurol 252(5):564–569CrossRefPubMed

60.

Holmberg J, Karlberg M, Harlacher U et al (2006) Treatment of phobic postural vertigo. A controlled study of cognitive-behavioral therapy and self-controlled desensitization. J Neurol 253(4):500–506CrossRefPubMed

61.

Holmberg J, Karlberg M, Harlacher U, Magnusson M (2007) One-year follow-up of cognitive behavioral therapy for phobic postural vertigo. J Neurol 254:1189–1192CrossRefPubMed

62.

Tschan R, Eckhardt-Henn A, Scheurich V et al (2012) Steadfast – effectiveness of a cognitive-behavioral self-management program for patients with somatoform vertigo and dizziness. Psychother Psychosom Med Psychol 62(3–4):111–119

63.

Lahmann C, Henningsen P, Dieterich M et al (2015) Tailored care for somatoform vertigo/dizziness: study protocol for a randomised controlled trial evaluating integrative group psychotherapy. J Neurol 262(8):1867–1875CrossRefPubMed

64.

Klockgether T (2012) Sporadic adult-onset ataxia of unknown etiology. Handb Clin Neurol 103:253–262CrossRefPubMed

65.

Feil K, Claassen J, Bardins S et al (2013) Effect of chlorzoxazone in patients with downbeat nystagmus: a pilot trial. Neurology 81(13):1152–1158CrossRefPubMed

66.

Strupp M, Schuler O, Krafczyk S et al (2003) Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology 61(2):165–170CrossRefPubMed

67.

Claassen J, Spiegel R, Kalla R et al (2013) A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus – effects on slowphase eye velocity, postural stability, locomotion and symptoms. J Neurol Neurosurg Psychiatry 84(12):1392–1399CrossRefPubMed

68.

Schniepp R, Wuehr M, Neuhaeusser M et al (2012) 4-Aminopyridine and cerebellar gait: a retrospective case series. J Neurol 259(11):2491–2493CrossRefPubMed

69.

Strupp M, Teufel J, Habs M et al (2013) Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J Neurol 260(10):2556–2561PubMedCentralCrossRefPubMed

70.

Bremova T, Malinova V, Amraoui Y et al (2015) Acetyl-dl-leucine in Niemann-Pick type C: a case series. Neurology 85(16):1386–1375CrossRef

Titel: Periphere, zentrale und funktionelle Schwindelsyndrome
verfasst von: Prof. Dr. Dr. h.c. M. Strupp, FANA, FEAN
M. Dieterich
A. Zwergal
T. Brandt
Publikationsdatum: 01.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Der Nervenarzt / Ausgabe 12/2015
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-015-4425-3

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2015

Nichtinvasive Hirnstimulation

Hirnstimulationsverfahren zur Behandlung schizophrener Psychosen

Therapeutischer Einsatz von Closed-loop-Hirnstimulation

„Time is brain“ – auch bei der schubförmigen Multiplen Sklerose

Hemikraniektomie beim älteren Menschen. Kontra

Wert und Akzeptanz einer Alzheimer-Risikodiagnostik